{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:45:20Z","timestamp":1776091520421,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postgraduate Research & Practice Innovation Program of Jiangsu Province","award":["KYCX24_2074"],"award-info":[{"award-number":["KYCX24_2074"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2074123"],"award-info":[{"award-number":["2074123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13785-4","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:23:18Z","timestamp":1764156198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term cost-effectiveness of pharmacist-managed hypertension care in China"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4383-9934","authenticated-orcid":false,"given":"Jingxuan","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuying","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haomin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-8061","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"13785_CR1","unstructured":"WHO. Global report on hypertension: the race against a silent killer. 2023. Available at: 14 April 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240081062."},{"key":"13785_CR2","doi-asserted-by":"publisher","unstructured":"Committee of the Report on Cardiovascular Health Diseases. Report on cardiovascular health and diseases in China 2022: an updated summary. Biomed Environ Sci. 2023;36(8). https:\/\/doi.org\/10.26599\/1671-5411.2023.06.001.","DOI":"10.26599\/1671-5411.2023.06.001"},{"key":"13785_CR3","doi-asserted-by":"publisher","unstructured":"Qi L, Yanbo Z, Tingting G, Kun Y, Kunquan G, Xinwen M, et al. Association of lifestyle factors and antihypertensive medication use with risk of all-cause and cause-specific mortality among adults with hypertension in China. JAMA Netw Open. 2022;5(2). https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.46118.","DOI":"10.1001\/jamanetworkopen.2021.46118"},{"issue":"07","key":"13785_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.16439\/j.issn.1673-7245.2024.07.002","volume":"32","author":"China Hypertension Prevention Guideline Revision Committee","year":"2024","unstructured":"China Hypertension Prevention Guideline Revision Committee. Guidelines for the prevention and treatment of hypertension in China (2024 revised edition). Chin J Hypertens. 2024;32(07):603\u2013700. https:\/\/doi.org\/10.16439\/j.issn.1673-7245.2024.07.002.","journal-title":"Chin J Hypertens"},{"issue":"04","key":"13785_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.13493\/j.issn.1672-7878.2023.04-019","volume":"20","author":"Z Qingling","year":"2023","unstructured":"Qingling Z. Evaluation of the application effect of multidisciplinary collaborative management involving pharmacists in the management of chronic diseases. Anti-infection Pharm. 2023;20(04):418\u201321. https:\/\/doi.org\/10.13493\/j.issn.1672-7878.2023.04-019.","journal-title":"Anti-infection Pharm"},{"key":"13785_CR6","unstructured":"National Health Commission, National Bureau of Traditional Chinese Medicine, National Disease Control Bureau, National Medical Service Project Technical Specification (2023 Edition). 2023. Available at: 14 April 2025. http:\/\/www.nhc.gov.cn\/caiwusi\/s7785t\/202309\/914aec9618944ee2b36621d33517e576\/files\/02f4d852dba34173a8dae7eab634f923.pdf."},{"key":"13785_CR7","doi-asserted-by":"publisher","unstructured":"Ying L, Guoqin L, Chaojie L, Xianhong W, Yalin C, Xiaoqin L, et al. Effects of pharmacist intervention on community control of hypertension: a randomized controlled trial in Zunyi, China. Glob Health Sci Pract. 2021;9(4). https:\/\/doi.org\/10.9745\/ghsp-d-20-00505.","DOI":"10.9745\/ghsp-d-20-00505"},{"issue":"1","key":"13785_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5897\/AJPP11.633","volume":"6","author":"PX Zhao","year":"2012","unstructured":"Zhao PX, Wang C, Qin L, Yuan M, Wen AD. Effect of clinical pharmacists\u2019s pharmaceutical care intervention to control hypertensive outpatients in China. Afr J Pharm Pharmacol. 2012;6(1):48\u201356. https:\/\/doi.org\/10.5897\/AJPP11.633.","journal-title":"Afr J Pharm Pharmacol"},{"issue":"9","key":"13785_CR9","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/strokeaha.119.025553","volume":"50","author":"X Xing","year":"2019","unstructured":"Xing X, Yang X, Liu F, Li J, Chen J, Liu X, et al. Predicting 10-Year and lifetime stroke risk in Chinese population. Stroke. 2019;50(9):2371\u20138. https:\/\/doi.org\/10.1161\/strokeaha.119.025553.","journal-title":"Stroke"},{"issue":"1","key":"13785_CR10","doi-asserted-by":"publisher","first-page":"e0170238","DOI":"10.1371\/journal.pone.0170238","volume":"12","author":"L Hu","year":"2017","unstructured":"Hu L, Huang X, You C, Li J, Hong K, Li P, et al. Prevalence and risk factors of prehypertension and hypertension in Southern China. PLoS ONE. 2017;12(1):e0170238. https:\/\/doi.org\/10.1371\/journal.pone.0170238.","journal-title":"PLoS ONE"},{"issue":"1","key":"13785_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12944-019-1000-0","volume":"18","author":"M Wang","year":"2019","unstructured":"Wang M, Hou X, Hu W, Chen L, Chen S. Serum lipid and lipoprotein levels of middle-aged and elderly Chinese men and women in Shandong Province. Lipids Health Dis. 2019;18(1):58. https:\/\/doi.org\/10.1186\/s12944-019-1000-0.","journal-title":"Lipids Health Dis"},{"key":"13785_CR12","doi-asserted-by":"publisher","unstructured":"Xueli Y, Jianxin L, Dongsheng H, Jichun C, Ying L, Jianfeng H, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (Prediction for ASCVD risk in China). Circulation. 2016;134(19). https:\/\/doi.org\/10.1161\/circulationaha.116.022367.","DOI":"10.1161\/circulationaha.116.022367"},{"key":"13785_CR13","doi-asserted-by":"publisher","unstructured":"Vuyisile TN, Julius MG, Thomas NS, John SG, Christopher GS, Maurice ES. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540). https:\/\/doi.org\/10.1016\/s0140-6736(06)69208-8.","DOI":"10.1016\/s0140-6736(06)69208-8"},{"key":"13785_CR14","doi-asserted-by":"publisher","unstructured":"Xinyue D, Xiaoning H, Jing W. Cost effectiveness of the first-in-class ARNI (Sacubitril\/Valsartan) for the treatment of essential hypertension in a Chinese setting. Pharmacoeconomics. 2022;40(12). https:\/\/doi.org\/10.1007\/s40273-022-01182-2.","DOI":"10.1007\/s40273-022-01182-2"},{"key":"13785_CR15","doi-asserted-by":"publisher","unstructured":"Richard G, John H, Colin G. Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field. Health Policy. 2003;64(3). https:\/\/doi.org\/10.1016\/s0168-8510(02)00184-7.","DOI":"10.1016\/s0168-8510(02)00184-7"},{"key":"13785_CR16","doi-asserted-by":"publisher","unstructured":"Lauren S, Adam A, Jon C, Nick F, Stephanie C, Mori K. Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk. BMC Public Health. 2019;19(1). https:\/\/doi.org\/10.1186\/s12889-019-7573-8.","DOI":"10.1186\/s12889-019-7573-8"},{"issue":"s1","key":"13785_CR17","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1111\/j.1524-4733.2006.00150.x","volume":"10","author":"JJC Facp","year":"2010","unstructured":"Facp JJC, Rn C, Hollenbeak JAOB, Eldon Spackman CS, Msph MA. Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles. Value Health. 2010;10(s1):S12\u201320. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00150.x.","journal-title":"Value Health"},{"key":"13785_CR18","doi-asserted-by":"publisher","unstructured":"Tianyu F, Xiaolin Z, Jiaying X, Shang G, Xihe Y. Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis. Int J Equity Health. 2025;24(1). https:\/\/doi.org\/10.1186\/s12939-025-02391-9.","DOI":"10.1186\/s12939-025-02391-9"},{"key":"13785_CR19","unstructured":"National Bureau of Statistics of China. China population and employment statistics yearbook. 2023. [Internet]. [cited 2025 April 14]. Available from: https:\/\/www.stats.gov.cn\/sj\/ndsj\/2023\/indexch.htm"},{"key":"13785_CR20","unstructured":"National Health Commission of the People\u2019s Republic of China. Health statistical yearbook. 2023 [Internet]. [cited 2025 April 14]. Available from: http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202305\/6ef68aac6bd14c1eb9375e01a0faa1fb.shtml"},{"key":"13785_CR21","doi-asserted-by":"publisher","unstructured":"Leyi L, Taihang S, Hao L, Mingye Z, Wenxi T. Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China. BMC Public Health. 2023;23(1). https:\/\/doi.org\/10.1186\/s12889-023-16458-1.","DOI":"10.1186\/s12889-023-16458-1"},{"key":"13785_CR22","doi-asserted-by":"publisher","unstructured":"Lei T, Shihui F, Mengyuan L, Xinrui Z, Hongchao L. Cost-effectiveness analysis of sodium zirconium cyclosilicate for treating hyperkalemia among Chinese patients. Front Public Health. 2023;11(0). https:\/\/doi.org\/10.3389\/fpubh.2023.1196789.","DOI":"10.3389\/fpubh.2023.1196789"},{"key":"13785_CR23","doi-asserted-by":"publisher","unstructured":"Zhuolin Z, Lele C, Hong W, Xinglu X, Wenqing F, Xuan H, et al. Paricalcitol versus calcitriol\u2009+\u2009cinacalcet for the treatment of secondary hyperparathyroidism in chronic kidney disease in China: a cost-effectiveness analysis. Front Public Health. 2021;9(0). https:\/\/doi.org\/10.3389\/fpubh.2021.712027.","DOI":"10.3389\/fpubh.2021.712027"},{"key":"13785_CR24","doi-asserted-by":"publisher","unstructured":"Jiali F, Wanji Z, Wei L, Juan X, Lan Z, Shihe L, et al. Cost-effectiveness of intensive versus standard blood pressure treatment in older patients with hypertension in China. Hypertension. 2022;79(11). https:\/\/doi.org\/10.1161\/hypertensionaha.122.20051.","DOI":"10.1161\/hypertensionaha.122.20051"},{"key":"13785_CR25","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.lanwpc.2023.100962","volume":"42","author":"J Li","year":"2024","unstructured":"Li J, Zhao D, Cai J, Chen S, Wu S, Qi Y. Cost-effectiveness of treatment in adults with blood pressure of 130\u2013139\/80\u201389 mmhg and high cardiovascular risk in china: a modelling study. Lancet Reg Health Western Pac. 2024;42:100962. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100962.","journal-title":"Lancet Reg Health Western Pac"},{"key":"13785_CR26","unstructured":"China Pharmaceutical Association. China Guidelines for Pharmacoeconomic Evaluations (2020 edition). Available from: 2025 Aug 9. https:\/\/consultor-salud.com\/wp-content\/upload-\/2021\/06\/China-Guidelines-for-Pharmacoeconomic-Evaluations-2020.pdf?utm_source=chatgpt.com."},{"key":"13785_CR27","doi-asserted-by":"publisher","first-page":"04147","DOI":"10.7189\/jogh.13.04147","volume":"13","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Deng H, Wang G, Chen S, Xing A, Wang Y, et al. Cost-effectiveness of drug treatment for young and middle-aged stage 1 hypertensive patients with high risk. J Global Health. 2023;13:04147. https:\/\/doi.org\/10.7189\/jogh.13.04147.","journal-title":"J Global Health"},{"key":"13785_CR28","doi-asserted-by":"publisher","unstructured":"Jian M, Guanqi H, Yingrui X, Paul M, Micha\u0142 P, Hongchao L. Cost-effectiveness of finerenone in addition to standard of care for patients with chronic kidney disease and type 2 diabetes in China. Adv Ther. 2024;41(8). https:\/\/doi.org\/10.1007\/s12325-024-02906-w.","DOI":"10.1007\/s12325-024-02906-w"},{"issue":"07","key":"13785_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.16439\/j.issn.1673-7245.2024.07.002","volume":"32","author":"Chinese Hypertension Prevention Gui","year":"2024","unstructured":"Chinese Hypertension Prevention Guideline Committee. Chinese hypertension prevention guideline (2024 Edition). Chin J Hypertens. 2024;32(07):603\u2013700. https:\/\/doi.org\/10.16439\/j.issn.1673-7245.2024.07.002.","journal-title":"Chin J Hypertens"},{"key":"13785_CR30","doi-asserted-by":"publisher","unstructured":"Peng Z, Jie L, Conglin W, Wei Z, Yanqiu Z, Hongfei G, et al. Strict target blood pressure management for reducing the stroke risk according to 2017 ACC\/AHA blood pressure guideline. Aging. 2019;11(16). https:\/\/doi.org\/10.18632\/aging.102207.","DOI":"10.18632\/aging.102207"},{"issue":"12","key":"13785_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11906-019-0996-x","volume":"21","author":"C Derington","year":"2019","unstructured":"Derington C, King J, Bryant K, McGee B, Moran A, Weintraub W, et al. Cost-Effectiveness and challenges of implementing intensive blood pressure goals and Team-Based care. Curr Hypertens Rep. 2019;21(12):91. https:\/\/doi.org\/10.1007\/s11906-019-0996-x.","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"13785_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1161\/hypertensionaha.115.06023","volume":"66","author":"L Polgreen","year":"2015","unstructured":"Polgreen L, Han J, Carter B, Ardery G, Coffey C, Chrischilles E, et al. Cost-Effectiveness of a Physician-Pharmacist collaboration intervention to improve blood pressure control. Hypertens (Dallas Tex: 1979). 2015;66(6):1145\u201351. https:\/\/doi.org\/10.1161\/hypertensionaha.115.06023.","journal-title":"Hypertens (Dallas Tex: 1979)"},{"issue":"24","key":"13785_CR33","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1161\/circulationaha.120.051683","volume":"143","author":"K Bryant","year":"2021","unstructured":"Bryant K, Moran A, Kazi D, Zhang Y, Penko J, Ruiz-Negr\u00f3n N, et al. Cost-Effectiveness of hypertension treatment by pharmacists in black barbershops. Circulation. 2021;143(24):2384\u201394. https:\/\/doi.org\/10.1161\/circulationaha.120.051683.","journal-title":"Circulation"},{"issue":"11","key":"13785_CR34","doi-asserted-by":"publisher","first-page":"e2341408","DOI":"10.1001\/jamanetworkopen.2023.41408","volume":"6","author":"D Dixon","year":"2023","unstructured":"Dixon D, Johnston K, Patterson J, Marra C, Tsuyuki R. Cost-Effectiveness of pharmacist prescribing for managing hypertension in the united States. JAMA Netw Open. 2023;6(11):e2341408. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.41408.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"13785_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1715163517701109","volume":"150","author":"C Marra","year":"2017","unstructured":"Marra C, Johnston K, Santschi V, Tsuyuki R. Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharmacists Journal: CPJ = Revue Des Pharmaciens Du Can : RPC. 2017;150(3):184\u201397. https:\/\/doi.org\/10.1177\/1715163517701109.","journal-title":"Can Pharmacists Journal: CPJ = Revue Des Pharmaciens Du Can : RPC"},{"key":"13785_CR36","doi-asserted-by":"publisher","unstructured":"Steven PD, Michael VM, Nicole KT, Stephen EA, Anna RB, Rachel AN, et al. Economic evaluation of the home blood pressure telemonitoring and pharmacist case management to control hypertension (Hyperlink) trial. J Am Coll Clin Pharm. 2018;1(1). https:\/\/doi.org\/10.1002\/jac5.1001.","DOI":"10.1002\/jac5.1001"},{"key":"13785_CR37","doi-asserted-by":"publisher","unstructured":"Raj SP, Helen S, Peter WW, Finlay AM, Muzaffar S, Colleen MN, et al. Cost-effectiveness of home blood pressure telemonitoring and case management in the secondary prevention of cerebrovascular disease in Canada. J Clin Hypertens (Greenwich). 2019;21(2):159\u201368. https:\/\/doi.org\/10.1111\/jch.13459","DOI":"10.1111\/jch.13459"},{"key":"13785_CR38","doi-asserted-by":"publisher","unstructured":"Antonio A-C, Camila Q, Francisco JM-M, Jos\u00e9 Cristian P-P, Shalom B, Victoria G-C. Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review. Eur J Health Econ. 2019;20(7). https:\/\/doi.org\/10.1007\/s10198-019-01080-z.","DOI":"10.1007\/s10198-019-01080-z"},{"key":"13785_CR39","doi-asserted-by":"publisher","first-page":"903270","DOI":"10.3389\/fphar.2022.903270","volume":"13","author":"S Costa","year":"2022","unstructured":"Costa S, Guerreiro J, Teixeira I, Helling D, Pereira J, Mateus C. Cost-effectiveness and cost-utility of hypertension and hyperlipidemia collaborative management between pharmacies and primary care in Portugal alongside a trial compared with usual care (USFarm\u00e1cia). Front Pharmacol. 2022;13:903270. https:\/\/doi.org\/10.3389\/fphar.2022.903270.","journal-title":"Front Pharmacol"},{"key":"13785_CR40","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fphar.2019.00210","volume":"10","author":"J Bosmans","year":"2019","unstructured":"Bosmans J, van der Laan D, Yang Y, Elders P, Boons C, Nijpels G, et al. The Cost-Effectiveness of an intervention program to enhance adherence to antihypertensive medication in comparison with usual care in community pharmacies. Front Pharmacol. 2019;10:210. https:\/\/doi.org\/10.3389\/fphar.2019.00210.","journal-title":"Front Pharmacol"},{"key":"13785_CR41","doi-asserted-by":"publisher","unstructured":"Mei Z, Yu S, Bin Z, Zhengjing H, Zhenping Z, Chun L, et al. Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey. BMJ. 2023;380(0). https:\/\/doi.org\/10.1136\/bmj-2022-071952.","DOI":"10.1136\/bmj-2022-071952"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13785-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13785-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13785-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:04:03Z","timestamp":1767470643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-025-13785-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13785"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13785-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. In this study, we only used mathematical modeling to evaluate the economic outcomes of management strategies using data derived exclusively from a previously published study. Thus, no ethical approval was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}